Therapeutic Potential of Oral Factor Xa Inhibitors List of authors.

Venous thromboembolism is the third leading cause of cardiovascular death, after myocardial infarction and stroke.¹ Total hip or knee arthroplasty is the procedure with the highest risk of venous thromboembolism.² In this issue of the Journal, two studies affirm and extend the efficacy and safety of the novel oral factor Xa inhibitors, rivaroxaban and apixaban, in the management of venous thromboembolic disease.^3,4